| Add to balance / Manage account | User: | Log out |
| Prospect News home > News index > List of issuers Y > Headlines for YM BioSciences Inc. > News item |
YM BioSciences licenses nimotuzumab to Singapore's Innogene Kalbiotech
New York, Nov. 17 - YM BioSciences Inc. announced its CIMYM Inc. majority-owned subsidiary has licensed its humanized EGF receptor-targeting monoclonal antibody nimotuzumab to Innogene Kalbiotech Ltd. of Singapore.
YM will receive an upfront payment of $1 million, milestones and a royalty on sales.
Countries covered by the license are Singapore, Taiwan, Thailand, Indonesia, Malaysia, the Philippines and South Africa plus some other emerging markets.
Innogene Kalbiotech will be responsible for development costs in its territories and will also undertake the registration in its territories of all other indications developed by CIMYM and its licensees elsewhere as well as those of other licensees of CIMAB SA, YM's partner in CIMYM Inc.
"This agreement is another milestone in our strategy to expand nimotuzumab's market potential by partnering with a major regional pharmaceutical company," said David Allan, chairman and chief executive officer of YM BioSciences, in a news release. Innogene Kalbiotech "will initially target head and neck cancer for which it proposes to file INDs in its territories for a study combining nimotuzumab and radiation. Subsequently, additional trials in other cancers are anticipated."
Nimotuzumab has not only demonstrated efficacy, it also has the unique side-effect profile of an absence of rash, diarrhea or conjunctivitis demonstrated by the other products targeting the EGFR pathway, YM said in a news release. Nimotuzumab was recently approved in China based on a 75% improvement in the complete response rate in patients diagnosed with squamous cell nasopharyngeal carcinoma (91% in patients treated with nimotuzumab plus radiotherapy versus 52% for those treated with radiotherapy alone).
YM BioSciences is a Mississauga, Ont., cancer drug development company. Innogene Kalbiotech is the biotech subsidiary of PT Kalbe Farma Tbk., Indonesia's largest public pharmaceutical company.
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.